Summary:
- Cassava Sciences’ stock has declined significantly since its peak, with ongoing skepticism about the efficacy of its Alzheimer’s drug, simufilam.
- Phase 3 trial results for simufilam are anticipated by year-end, which could either validate or disprove its effectiveness.
- Cassava has faced legal and scientific scrutiny, with key figures resigning and the company settling a $40m SEC penalty.
- The new CEO remains cautiously optimistic but acknowledges the potential for ambiguous results and the need for further FDA consultations.
Kim_white/iStock via Getty Images
Investment Thesis
Cassava Sciences (NASDAQ:SAVA) reported its Q3 earnings today, Thursday Nov. 7. Nearly four years ago to the day, Cassava stock traded >$90 per share, and there was genuine hope that its lead product, simufilam, an oral pill with almost no side effects, could not only
Analyst’s Disclosure: I/we have a beneficial long position in the shares of SAVA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth. Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.